Radiopharm Theranostics Ltd
RADX
Company Profile
Business description
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Contact
62 Lygon Street
Suite 1, Level 3, Carlton South
MelbourneVIC3053
AUST: +61 398245254
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 June 2026
Employees
14
Stocks News & Analysis
stocks
2 ASX shares that benefit from sticky inflation
Inflation is a key risk to shareholders. Here’s why these two ASX shares benefit from higher inflation.
stocks
Undervalued ASX retailer benefiting from rebound in spending
Uplift in sales momentum continues.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,870.10 | 21.70 | 0.25% |
| CAC 40 | 8,106.16 | 0.00 | 0.00% |
| DAX 40 | 24,076.87 | 153.04 | -0.63% |
| Dow JONES (US) | 48,114.26 | 302.30 | -0.62% |
| FTSE 100 | 9,684.79 | 66.52 | -0.68% |
| HKSE | 25,235.41 | 393.47 | -1.54% |
| NASDAQ | 23,111.46 | 54.05 | 0.23% |
| Nikkei 225 | 49,383.29 | 784.82 | -1.56% |
| NZX 50 Index | 13,390.46 | 34.49 | -0.26% |
| S&P 500 | 6,800.26 | 16.25 | -0.24% |
| S&P/ASX 200 | 8,584.00 | 20.40 | 0.24% |
| SSE Composite Index | 3,824.81 | 43.11 | -1.11% |